Submit a Letter to the Editor for:
Yoshiaki Kido, Deborah J. Burks, Dominic Withers, Jens C. Bruning, C. Ronald Kahn, Morris F. White, Domenico Accili
J Clin Invest. 2000;
105(2):199
doi:10.1172/JCI7917
Abstract |
Full text
|
PDF
T
ype 2 diabetes is characterized by abnormalities of insulin action in muscle, adipose tissue, and liver and by altered β-cell function. To analyze the role of the insulin signaling pathway in these processes, we have generated mice with combined heterozygous null mutations in insulin receptor (ir), insulin receptor substrate (irs-1), and/or irs-2. Diabetes developed in 40% of ir/irs-1/irs-2+/–, 20% of ir/irs-1+/–, 17% of ir/irs-2+/–, and 5% of ir+/– mice. Although combined heterozygosity for ir/irs-1+/– and ir/irs-2+/– results in a similar number of diabetic mice, there are significant differences in the underlying metabolic abnormalities. ir/irs-1+/– mice develop severe insulin resistance in skeletal muscle and liver, with compensatory β-cell hyperplasia. In contrast, ir/irs-2+/– mice develop severe insulin resistance in liver, mild insulin resistance in skeletal muscle, and modest β-cell hyperplasia. Triple heterozygotes develop severe insulin resistance in skeletal muscle and liver and marked β-cell hyperplasia. These data indicate tissue-specific differences in the roles of IRSs to mediate insulin action, with irs-1 playing a prominent role in skeletal muscle and irs-2 in liver. They also provide a practical demonstration of the polygenic and genetically heterogeneous interactions underlying the inheritance of type 2 diabetes.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
